Ema Invest Information

Pharmaceuticals
EMA Validates Marketing Application for Tisotumab Vedotin, A Potential Treatment for Recurrent or Metastatic Cervical Cancer Feb 3, 2024
Companies
Bristol Myers Squibb's Repotrectinib Under EMA Review for NSCLC Treatment Jan 4, 2024